In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

In a new era of Alzheimer’s disease research, the emergence of blockbuster therapies like Eli Lilly’s Kisunla (donanemab) and ...

AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...

Allarity maintains a cash balance of $18.5 million, sufficient to advance and accelerate stenoparib's clinical development ...

An Osaka Metropolitan University-led team evaluated the effects of SGLT2 inhibitors in protecting the kidneys, showing that ...

We were all shocked when word slipped out that Jumana Murad was a married lady! The whole deal was very quick to come to pass ...

Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...

Biogen (BIIB – Research Report) received a Hold rating and price target from Needham analyst Ami Fadia today. The company’s shares closed last Friday at $159.99. Don't Miss our Black Friday Offers: ...

But when the Japanese are craving a city getaway, they head south to Fukuoka. Nestled between the mountains and the sea on ...

OPUVIZ is one of the first wave aflibercept biosimilars in Europe OPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under Samsung Bioepis and Biogen's partnership EC ...